Tag:

Amgen

Latest Headlines

Latest Headlines

Amgen makes deep job cuts to position itself for post Enbrel-world

When California biotech Amgen picked up Onyx Pharmaceuticals a year ago for $10.4 billion to get its hands on the multiple myeloma drug Kyprolis, investors were wondering what the future would hold for the world's largest biotech. CEO Robert Bradway at least partially answered that question Tuesday saying the company would ax 15% of its workforce.

UPDATED: Amgen axing up to 2,900 staffers, shuttering R&D campus in revamp

Bracing for an expensive round of late-stage studies and potential drug launches as it ramps up work on a slate of new biosimilars, Amgen reported Tuesday evening that it plans to trim up to 15% of the company's workforce, shutting down facilities in Colorado and Washington state as it slashes up to 2,900 staffers.

FDA opens the door for a Novartis biosimilar of Amgen's Neupogen

The FDA accepted Novartis' application to sell a knockoff of Amgen's biological treatment Neupogen, making the company a pioneer among those looking to capitalize on a soon-to-come U.S. market for biosimilars that is expected to explode.

Amgen's kidney dialysis drug clears its first Phase III hurdle

Amgen's in-development treatment for patients on kidney dialysis met its primary and secondary goals in a late-stage trial, step one in the drug's three-part Phase III program.

Which big brands will still be bringing in the big bucks in 2020?

Best-selling drugs did well for themselves in 2013, churning out more than $76 billion in sales. But big-name brands could stand the test of time and help the top 10 rake in more than $80 billion in 2020, according to a new report.

Amgen scores FDA's 'breakthrough' nod for prospective leukemia therapy

Amgen nabbed a breakthrough designation for its mid-stage blood cancer drug blinatumomab.

Angling for early OK, Amgen wins 'breakthrough' title for leukemia drug

Amgen has scored boasting rights to a breakthrough drug designation from the FDA for its promising mid-stage leukemia drug blinatumomab.

Some cancer docs still bill heavily for Amgen's Epogen despite safety questions

Many cancer doctors have cut back on their use of Amgen's anemia drug Epogen--also sold as Procrit by Johnson & Johnson--because of safety questions that arose over the past few years. But as The Wall Street Journal reports, one Florida doctors' group still administers the drug in quantity, accounting for one-sixth of related Medicare charges in 2012.

Analyst: Amgen's moonshot R&D spending is bad for business

Amgen is hardly gun shy about high-risk, high-reward R&D bets, but the Big Biotech's swing-for-the-fences approach to research is bad for the bottom line, according to Bernstein analyst Geoffrey Porges. 

Amgen to pursue T-Vec approval despite PhIII survival miss

Back in April, Amgen's cancer-fighting viral vaccine stumbled in Phase III, missing on overall survival, a secondary endpoint. But that won't stop the California company from seeking regulatory approval, it announced early this week.